Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome

Journal of Rheumatology

Volumn 34, Issue 9, 2007, Pages 1882-1887

  Hjortnaes, Jesper ^a   Algra, Ale ^a,b   Olijhoek, Jobien ^a   Huisman, Margriet ^a   Jacobs, Johannes ^a   Van Der Graaf, Yolanda ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Epidemiology; Metabolic syndrome; Serum uric acid; Vascular disease

Indexed keywords

URIC ACID;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTERY DISEASE; ARTICLE; CEREBRAL ARTERY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; URIC ACID BLOOD LEVEL; VASCULAR DISEASE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; URIC ACID;

EID: 35948992181     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
3. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005;111:1448-54.
4. Gorter PM, Olijhoek JK, Van der Graaf Y, Algra A, Rabelink TJ, Visseren FLJ. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebral vascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004;173:363-9.
5. Alderman MH, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79.
6. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Intern Med 2004;164:1546-51.
7. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-30.
8. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1993;78:25-9.
9. Wheeler JG, Juzwishin KDM, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. PloS Med 2005;2:e76.
10. Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes melllitus. Stroke 1998;29:635-9.
11. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol 2006;18:193-8.
12. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk for acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
13. Johnson RJ, Kang D, Feig D, et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90.
14. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2004;67:1739-42.
15. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2004;45:28-33.
16. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutrition Metab 2004;1:10.
17. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-7.
18. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
19. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality in the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10.
20. Franse LV, Pahor M, Dibari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-54.
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
22. Lee J, Sparrow D, Vokonas PS, Lansberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome: the Normative Aging Study. Am J Epidemiol 1995;142:288-94.
23. Facchni F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11.
24. Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. Annu Rev Nutr 2005;25: 17.1-17.16.
25. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141:637-44.
26. Reuanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl 1982;688:45-9.
27. Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricemia as a risk factor for cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-55.
28. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5 year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989;42:257-67.
29. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;5:773-81.
30. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
31. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
32. Liao Y, Kwon S, Shaughnessy S, et al. Critical Evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27:978-83.